Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Hasmukh Jain, Manju Sengar, Vasu Babu Goli, Jayashree Thorat, Prashant Tembhare, Dhanlaxmi Shetty, V. N. Avinash Bonda, Lingaraj Nayak, P. G. Subramanian, Bhausaheb Bagal, Nikhil Patkar, Neha Sharma, Himanshi Gupta, Sumeet Gujral

Blood Adv (2021) 5 (17): 3436–3444.

https://doi.org/10.1182/bloodadvances.2020003368

Published: 2021

Journal Articles

Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol

Akhil Rajendra, Hasmukh Jain, V. N. Avinash Bonda, Lingaraj Nayak, Prashant Tembhare, Dhanlaxmi Shetty, Jayashree Thorat, Hemani Jain, Papagudi Ganesan Subramanian, Nikhil Patkar, Gaurav Chatterjee, Navin Khattry, Anant Gokarn, Sachin Punatar, Smruti Mokal, Bhausaheb Bagal, Manju Sengar

Blood Adv (2021) 5 (5): 1178–1193.

https://doi.org/10.1182/bloodadvances.2020003526

Published: 2021

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplantation with omidubicel in sickle cell disease

Suhag Parikh, Joel A. Brochstein, Einat Galamidi, Aurélie Schwarzbach, Joanne Kurtzberg

Blood Adv (2021) 5 (3): 843–852.

https://doi.org/10.1182/bloodadvances.2020003248

Published: 2021

Includes: Supplemental data

Journal Articles

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation

Burak Kalin, Yvette van Norden, Michel van Gelder, Dimitri Breems, Johan Maertens, Mojca Jongen-Lavrencic, Annoek E. C. Broers, Eric Braakman, Tim Grob, Wendelien Zeijlemaker, Gert J. Ossenkoppele, Ellen Meijer, Jan J. Cornelissen

Blood Adv (2020) 4 (18): 4430–4437.

https://doi.org/10.1182/bloodadvances.2020002074

Published: 2020

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Adv (2020) 4 (16): 3977–3989.

https://doi.org/10.1182/bloodadvances.2020001956

Published: 2020

Journal Articles

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant

Seongseok Yun, Onyee Chan, Daniel Kerr, Nicole D. Vincelette, Afshan Idrees, Qianxing Mo, Kendra Sweet, Jeffrey E. Lancet, Mohamed A. Kharfan-Dabaja, Ling Zhang, Lubomir Sokol

Blood Adv (2020) 4 (14): 3435–3442.

https://doi.org/10.1182/bloodadvances.2020001875

Published: 2020

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

Bart L. Scott

Blood Adv (2020) 4 (13): 3200–3204.

https://doi.org/10.1182/bloodadvances.2019000388

Published: 2020

Journal Articles

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity

Blood Adv (2020) 4 (7): 1296–1306.

https://doi.org/10.1182/bloodadvances.2019000638

Published: 2020

Journal Articles

Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia

Blood Adv (2020) 4 (6): 983–992.

https://doi.org/10.1182/bloodadvances.2019001126

Published: 2020

Includes: Supplemental data

Journal Articles

Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation

Taiki Ando, Takayoshi Tachibana, Masatsugu Tanaka, Taisei Suzuki, Yasufumi Ishiyama, Satoshi Koyama, Eriko Ogusa, Ayumi Numata, Kenji Matsumoto, Heiwa Kanamori, Hideaki Nakajima

Blood Adv (2020) 4 (2): 408–419.

https://doi.org/10.1182/bloodadvances.2019001021

Published: 2020

Includes: Supplemental data

Journal Articles

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation

Andrea S. Henden, Antiopi Varelias, Justine Leach, Elise Sturgeon, Judy Avery, Jessica Kelly, Stuart Olver, Luke Samson, Gunter Hartel, Simon Durrant, Jason Butler, Anthony J. Morton, Ashish Misra, Siok-Keen Tey, Elango Subramoniapillai, Cameron Curley, Glen Kennedy, Geoffrey R. Hill

Blood Adv (2019) 3 (20): 3013–3019.

https://doi.org/10.1182/bloodadvances.2019000453

Published: 2019

Includes: Supplemental data

Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Blood Adv (2019) 3 (6): 922–933.

https://doi.org/10.1182/bloodadvances.2018026989

Published: 2019

Includes: Supplemental data

Journal Articles

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Blood Adv (2018) 2 (24): 3608–3617.

https://doi.org/10.1182/bloodadvances.2018023689

Published: 2018

Includes: Supplemental data

Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet

Blood Adv (2018) 2 (16): 2063–2071.

https://doi.org/10.1182/bloodadvances.2018015529

Published: 2018

Includes: Supplemental data

Journal Articles

Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens

Jefferson L. Lansford, Udara Dharmasiri, Shengjie Chai, Sally A. Hunsucker, Dante S. Bortone, James E. Keating, Ian M. Schlup, Gary L. Glish, Edward J. Collins, Gheath Alatrash, Jeffrey J. Molldrem, Paul M. Armistead, Benjamin G. Vincent

Blood Adv (2018) 2 (16): 2052–2062.

https://doi.org/10.1182/bloodadvances.2018022475

Published: 2018

Includes: Supplemental data

Journal Articles

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Tibor J. Kovacsovics, Alice Mims, Mohamed E. Salama, Jeremy Pantin, Narayanam Rao, Ken M. Kosak, Peter Ahorukomeye, Martha J. Glenn, Michael W. N. Deininger, Kenneth M. Boucher, Linda M. Bavisotto, Gerardo Gutierrez-Sanchez, Thomas P. Kennedy, Stephen G. Marcus, Paul J. Shami

Blood Adv (2018) 2 (4): 381–389.

https://doi.org/10.1182/bloodadvances.2017013391

Published: 2018

Journal Articles

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Prajwal Boddu, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval Daver, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Steven M. Kornblau

Blood Adv (2017) 1 (19): 1546–1550.

https://doi.org/10.1182/bloodadvances.2017009019

Published: 2017

Includes: Supplemental data

Journal Articles

ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint

Natasha Kekre, Joseph H. Antin

Blood Adv (2017) 1 (9): 573–576.

https://doi.org/10.1182/bloodadvances.2016001552

Published: 2017

Journal Articles

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point

Andrea Bacigalupo

Blood Adv (2017) 1 (9): 569–572.

https://doi.org/10.1182/bloodadvances.2016001560

Published: 2017

Journal Articles

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Blood Adv (2016) 1 (3): 250–259.

https://doi.org/10.1182/bloodadvances.2016001495

Published: 2016

Includes: Supplemental data

NARROW

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol

Allogeneic stem cell transplantation with omidubicel in sickle cell disease

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity

Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia

Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only